IP Library › Granted Patent US 8,119,661
Granted Patent B2
US 8,119,661 · App. 12/205,968 · Granted Feb 21, 2012

Piperidine derivatives and their use as muscarinic receptor modulators

Assignee: AstraZeneca AB
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,119,661
App. No.
12/205,968
Granted
Feb 21, 2012
Kind
B2
Abstract

Compounds of Formula I, or pharmaceutically acceptable salts thereof: wherein R 2 , R 3 , X, m and n are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.

Claims (1)

1. Propan-2-yl 4-[4-[(3aS,7aS)-2-oxo-3a,4,5,6,7,7a-hexahydro-3H-benzoimidazol-1-yl]-1-piperidyl]-4-methyl-piperidine-1-carboxylate or a pharmaceutically acceptable salt thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2008
From: CHENG, YUN-XING; LUO, XUEHONG; SANTHAKUMAR, VIJAYARATNAM; TOMASZEWSKI, MIROSLAW JERZY
To: ASTRAZENECA AB
Reel/Frame 021767/0523 →
Continuity (2)
Provisional Application 60971288 · Sep 11, 2007
Related Publication 20090076078A1 · Mar 19, 2009